PDT Partners’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

PDT Partners’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-59,100	Closed	-$242K	–	643
2017 Q4	$242K	Sell	59,100 -33,800	-36%	-$147K	0.01%	498
2017 Q3	$420K	Buy	+92,900	New	+$376K	0.01%	446
2017 Q1	–	Sell	-23,900	Closed	-$184K	–	579
2016 Q4	$184K	Sell	23,900 -300	-1%	-$2.76K	0.01%	473
2016 Q3	$277K	Sell	24,200 -300	-1%	-$3.49K	0.02%	419
2016 Q2	$302K	Sell	24,500 -250	-1%	-$3.03K	0.02%	377
2016 Q1	$250K	Buy	24,750 +8,050	+48%	+$94.5K	0.02%	488
2015 Q4	$376K	Buy	+16,700	New	+$342K	0.05%	301

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PDT Partners's OMED Position: Q1 2018 in Review

PDT Partners sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2018, closing a stake of 59,100 shares — an estimated $242K sold.

PDT Partners first reported a position in OMED in Q4 2015 and held it in 7 quarters. The position peaked at $420K in Q3 2017. 66 funds tracked by Wall St. Rank hold OMED as of Q1 2018.

PDT Partners reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
PDT Partners sold 59,100 OncoMed Pharmaceuticals, Inc. shares in Q1 2018, an estimated $242K.
PDT Partners first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2015 and held it in 7 quarters.
PDT Partners's OncoMed Pharmaceuticals, Inc. position peaked at $420K in Q3 2017.
66 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2018.

Based on PDT Partners's 13F filing for Q1 2018, filed 15 May 2018.